Evidence map›Paper›PMID 32783669›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Hippocampal Avoidance Whole-Brain Radiotherapy (WBRT) Versus WBRT in Patients With Brain Metastases: Were Hippocampi the Only Difference?

Antonin Levy, Frédéric Dhermain, Angela Botticella, Sofia Rivera, Cécile Le Péchoux

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Antonin LevyAntonin Levy, MD, PhD, Department of Radiation Oncology and INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France, and Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France; and Frédéric Dhermain, MD, PhD; Angela Botticella, MD; Sofia Rivera, MD, PhD; and Cécile Le Péchoux, MD, Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Frédéric DhermainAntonin Levy, MD, PhD, Department of Radiation Oncology and INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France, and Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France; and Frédéric Dhermain, MD, PhD; Angela Botticella, MD; Sofia Rivera, MD, PhD; and Cécile Le Péchoux, MD, Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Angela BotticellaAntonin Levy, MD, PhD, Department of Radiation Oncology and INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France, and Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France; and Frédéric Dhermain, MD, PhD; Angela Botticella, MD; Sofia Rivera, MD, PhD; and Cécile Le Péchoux, MD, Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Sofia RiveraAntonin Levy, MD, PhD, Department of Radiation Oncology and INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France, and Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France; and Frédéric Dhermain, MD, PhD; Angela Botticella, MD; Sofia Rivera, MD, PhD; and Cécile Le Péchoux, MD, Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Cécile Le PéchouxAntonin Levy, MD, PhD, Department of Radiation Oncology and INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France, and Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France; and Frédéric Dhermain, MD, PhD; Angela Botticella, MD; Sofia Rivera, MD, PhD; and Cécile Le Péchoux, MD, Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsMemantineCranial IrradiationHippocampusHumansMemantine

Identifiers

PMID32783669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.